
Part One: The Question of MRD in CLL Therapy
The HemOnc Pulse
Exploring the Selection of BTKIs in Frontline Therapy
Exploring the considerations for selecting BTKIs in frontline therapy, focusing on toxicity profiles, patient comorbidities, and the tolerability of second-generation BTKIs like Daniel and Calibrietinib. Emphasizing patient-specific factors over efficacy differences, this chapter raises unanswered questions in the field.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.